A Phase II, Multi-center, Open-label, Single-Arm Study to Evaluate the Efficacy and Safety of Oral LDK378 Treatment for Patients With ALK-Positive Non-Small Cell Lung Cancer Previously Treated With Alectinib
Phase of Trial: Phase II
Latest Information Update: 04 Apr 2017
At a glance
- Drugs Ceritinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 24 Mar 2017 Planned End Date changed from 1 Nov 2017 to 20 Dec 2017.
- 24 Mar 2017 Planned primary completion date changed from 1 Nov 2017 to 2 Aug 2017.
- 09 Sep 2016 Planned End Date changed from 1 Apr 2018 to 1 Nov 2017.